Penwest Begins Trial for Parkinson's Disease Treatment

A Phase I clinical trial is under way for PW 4153, Penwest Pharmaceuticals’ drug candidate for the treatment of Parkinson’s disease symptoms.

The drug is an extended-release reformulation of a marketed drug that is administered several times per day. The trial’s goal is to assess the bioavailability and pharmacokinetic blood levels of the drug formulation in healthy volunteers, Penwest said.

Results are expected by the fourth quarter of the year.